- Details
- Description
Strength:
Ibrutinib INN 140 mg
Composition:
Ibrutinib 140 mg
Treatment:
Certain B-cell malignancies / blood cancers
Form:
Capsule
Brand:
Ibruxen
Quantity Unit:
Capsules
Manufacturer:
Everest Pharmaceuticals Ltd.
Ibruxen (Ibrutinib INN 140 mg) is an oral targeted anticancer medicine listed by Everest Pharmaceuticals Ltd. under its Oncology products. It contains ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor that blocks signaling pathways involved in the growth and survival of certain B-cell cancers. It is used in the treatment of specific B-cell malignancies, including certain leukemias and lymphomas, under specialist medical supervision.
